正常肾功能人群中的成纤维细胞生长因子23、矿物质代谢与肥胖
在估算肾小球滤过率(eGFR)≥60 mL/min/1.73m²的人群中开展横断面分析,发现体质指数(BMI)、腰围、腰臀比及腹部脂肪面积越大,血清成纤维细胞生长因子23(FGF23)水平越高,且该关联独立于eGFR和血磷等已知混杂因素。
要点
- BMI越高,血清FGF23水平越高(未校正趋势P<0.0001)。
- BMI与FGF23的关联独立于已知混杂因素(校正β=每10 kg/m² FGF23高7.2%;P<0.0001)。
- 腹部脂肪面积亦独立与较高FGF23相关(P<0.01)。
核心结论
- 在肾功能正常的大队列中,肥胖与较高FGF23水平相关,且独立于eGFR和血磷等已知混杂因素。
- 需要进一步研究以评估肥胖程度较高时FGF23升高的原因及其对骨骼健康的潜在影响。
研究设计与样本
- 横断面分析,纳入eGFR≥60 mL/min/1.73m²的参与者。
- 粗略肥胖指标(BMI、腰围、腰臀比)分析样本量n=5610。
- 精细肥胖指标(CT测量的腹部脂肪面积)分析样本量n=1313。
- 采用多变量线性回归评估肥胖指标与FGF23的关联。
主要发现
- FGF23随BMI类别升高:BMI<25为37.7 pg/mL,BMI 25至29.99为38.7 pg/mL,BMI 30至39.99为39.8 pg/mL,BMI≥40为40.9 pg/mL(未校正趋势P<0.0001)。
- BMI与FGF23的关联独立于已知混杂因素(校正β=每10 kg/m² FGF23高7.2%;P<0.0001)。
- 使用腰围和腰臀比得到类似结果。
- 腹部脂肪面积亦独立与较高FGF23相关(P<0.01)。
- FGF23与肥胖的正向关联见于eGFR未下降且血磷未随肥胖升高的情况下。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以评估肥胖程度较高时FGF23升高的原因及其对骨骼健康的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Obesity is associated with poor bone mineralization and quality. Fibroblast growth factor 23 (FGF23) plays an important role in skeletal physiology. OBJECTIVE: To test hypothesis that greater adiposity results in higher FGF23 levels among individuals with normal estimated glomerular filtration rate (eGFR). DESIGN, SETTING, PARTICIPANTS: Cross-sectional analyses among participants with eGFR ≥60 mL/min/1.73m2. We assessed the association between crude [body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR); n = 5610] and refined (abdominal adipose tissue area by computed tomography; n = 1313) measures of adiposity and FGF23 using multivariable linear regression. MAIN OUTCOME MEASURE: Serum FGF23. RESULTS: FGF23 was higher across BMI categories (BMI <25: 37.7; BMI 25 to 29.99: 38.7; BMI 30 to 39.99: 39.8; BMI ≥40: 40.9 pg/mL, unadjusted P trend < 0.0001). The association between BMI and FGF23 was independent of known confounders of FGF23 (adjusted β = +7.2% higher FGF23 per 10 kg/m2; P < 0.0001). Similar results were observed using WC and WHR. Abdominal adipose tissue area was also independently associated with higher FGF23 (P < 0.01). Notably, the positive associations between FGF23 and adiposity were observed despite the fact that eGFR did not decline and serum phosphate levels did not increase with adiposity. CONCLUSION: In a large cohort with normal kidney function, adiposity was associated with higher FGF23 levels independent of known confounders, including eGFR and phosphate. Further studies are needed to evaluate the causes of higher FGF23 in settings of greater adiposity and the potential impact on skeletal health.
引用
- Zaheer S, de Boer IH, Allison M, et al. Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function. J Clin Endocrinol Metab. 2017. PMID: 28323987. doi:10.1210/jc.2016-3563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。